Metallothionein Expression and Roles During Neuropathology in the CNS.

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Metallothionein Expression and Roles During Neuropathology in the CNS. / Penkowa, Milena.

In: The Danish Medical Association Publishing House, Vol. 1, No. 1, 2006, p. 1-23.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Penkowa, M 2006, 'Metallothionein Expression and Roles During Neuropathology in the CNS.', The Danish Medical Association Publishing House, vol. 1, no. 1, pp. 1-23.

APA

Penkowa, M. (2006). Metallothionein Expression and Roles During Neuropathology in the CNS. The Danish Medical Association Publishing House, 1(1), 1-23.

Vancouver

Penkowa M. Metallothionein Expression and Roles During Neuropathology in the CNS. The Danish Medical Association Publishing House. 2006;1(1):1-23.

Author

Penkowa, Milena. / Metallothionein Expression and Roles During Neuropathology in the CNS. In: The Danish Medical Association Publishing House. 2006 ; Vol. 1, No. 1. pp. 1-23.

Bibtex

@article{8b00fc20833011de8bc9000ea68e967b,
title = "Metallothionein Expression and Roles During Neuropathology in the CNS.",
abstract = "  This doctoral thesis describes the expression and roles of Metallothioneins I and II (MT-I+II) during CNS pathology. MT-I+II expression increases significantly in reactive astrocytes and microglia/macrophages after traumatic brain injury (cryogenic lesion in cerebral cortex) and brain stem toxicity induced by the gliotoxin 6-aminonicotinamide (6-AN). Interleukin-6 (IL-6) is a key inducer of brain MT-I+II, as judged by using genetic IL-6 deficient mice (IL-6 knock-out (IL-6KO) mice) and IL-6 overexpressing (GFAP-IL6) mice subjected to brain injury. These studies also indicate that IL-6 and/or IL-6-induced MT-I+II exert neuroprotective functions. To study MT-I+II roles in CNS, genetically modified mice with MT-I+II deficiency (MT-I+II knock-out (MT-KO) mice) or transgenic MT-I overexpression (TgMT mice) were applied along wildtype controls; as well as wildtype, and MT-KO mice receiving exogenous MT-I or MT-II treatment were examined. Both MT-KO and TgMT genotypes and mice receiving exogenous MT were studied after cryogenic brain injury and 6-AN-induced toxicity in brain stem. These experiments overall show that MT-I+II have significant immunomodulating, antioxidant and neuroprotective roles. Accordingly, MT-I+II reduce CNS activation of macrophages and lymphocytes including expression of proinflammatory cytokines IL-1b, IL-6, IL-12 and TNF-a. Moreover, MT-I+II are antioxidant and antiapoptotic factors counteracting reactive oxygen species (ROS)/oxidative stress, neurodegeneration and apoptotic cell death, whereby the delayed (secondary) tissue damage was inhibited after brain injury and 6-AN-toxicity. MT-I+II also diminish the primary CNS toxicity caused directly by 6-AN and the clinical outcome (mortality). Additionally, MT-I+II stimulate astrogliosis; expression of growth factors, their receptors and neurotrophins (TGFb, TGFb-Receptor, bFGF, bFGF-Receptor, VEGF, NT-3, NT-4/5, NGF); angiogenesis; and growth cone formation. Hence, MT-I+II enhance CNS tissue repair as seen clearly after the cryogenic injury, after which MT-I+II promote substitution of the necrotic lesion cavity with a glial scar tissue including revascularization. In the surrounding tissue, MT-I+II stimulate growth cone formation and outgrowths of surviving neurons situated outside the lesioned area; while inside the lesion, normal neurons or neuronal cell bodies were never seen. The angiogenic actions of MT-I+II were supported by comparing various genotypes like GFAP-IL6 mice; MT-I+II deficient GFAP-IL6 (GFAP-IL6/MT-KO) mice; MT-I+II heterozygous GFAP-IL6 mice (GFAP-IL6-MT+/- mice); double-transgenic IL-6 and MT-I overexpressors (GFAP-IL6/TgMT mice); MT-KO mice; and TgMT mice. The IL-6 overexpressors are suitable for this as they spontaneously develop proliferative angiopathy/angiogenesis, which is inhibited by MT-I+II deficiency and enhanced by MT-I overexpression. In fact, angiogenesis was highest in the MT-I overexpressing TgMT and GFAP-IL6/TgMT mice, even though the TgMT mice show quite low IL-6 levels as MT-I+II inhibit brain IL-6 mRNA and protein. Moreover, GFAP-IL6/TgMT and TgMT and GFAP-IL6 genotypes were lesioned along wildtype controls in order to identify the roles of IL-6 versus MT-I+II. Although IL-6 induces CNS protection, this could be due to IL-6-induced MT-I+II, as neuroprotection and recovery are associated with MT-I+II levels only and not with IL-6 or inflammation: The more MT-I+II, the less neuropathology. The MT-I+II actions seen after brain injury and 6-AN-toxicity are induced by both endogenous MT-I overexpression and exogenous MT-II treatment. As presented here for the first time, analogous therapeutic effects are obtained after brain injury by using native or recombinant MT-I or MT-II derived from diverse non-mammalian and mammalian species like drosophila, mouse, rabbit, horse and human. Treatment with these MT-I and MT-II proteins significantly reduce inflammation, oxidative stress, neurodegeneration and apoptotic cell death after brain injury, while astroglia is stimulated. This indicates that MT-I+II function independently of species of origin. Previously, we showed that MT-I+II also ameliorate autoimmune, excitotoxic and inflammatory CNS disorders, and independent groups have confirmed this and have in fact added that MT-I+II are also major neuroprotective factors during ischemia and motor neuron disease. As emerging data validate these functions in human tissue and neurological patients, MT-I+II seem to demonstrate potentials as therapeutic targets for the treatment of CNS disorders.",
keywords = "Faculty of Health and Medical Sciences",
author = "Milena Penkowa",
note = "Paper id:: 87-7891-123-0",
year = "2006",
language = "English",
volume = "1",
pages = "1--23",
journal = "The Danish Medical Association Publishing House",
publisher = "The Danish Medical Association",
number = "1",

}

RIS

TY - JOUR

T1 - Metallothionein Expression and Roles During Neuropathology in the CNS.

AU - Penkowa, Milena

N1 - Paper id:: 87-7891-123-0

PY - 2006

Y1 - 2006

N2 -   This doctoral thesis describes the expression and roles of Metallothioneins I and II (MT-I+II) during CNS pathology. MT-I+II expression increases significantly in reactive astrocytes and microglia/macrophages after traumatic brain injury (cryogenic lesion in cerebral cortex) and brain stem toxicity induced by the gliotoxin 6-aminonicotinamide (6-AN). Interleukin-6 (IL-6) is a key inducer of brain MT-I+II, as judged by using genetic IL-6 deficient mice (IL-6 knock-out (IL-6KO) mice) and IL-6 overexpressing (GFAP-IL6) mice subjected to brain injury. These studies also indicate that IL-6 and/or IL-6-induced MT-I+II exert neuroprotective functions. To study MT-I+II roles in CNS, genetically modified mice with MT-I+II deficiency (MT-I+II knock-out (MT-KO) mice) or transgenic MT-I overexpression (TgMT mice) were applied along wildtype controls; as well as wildtype, and MT-KO mice receiving exogenous MT-I or MT-II treatment were examined. Both MT-KO and TgMT genotypes and mice receiving exogenous MT were studied after cryogenic brain injury and 6-AN-induced toxicity in brain stem. These experiments overall show that MT-I+II have significant immunomodulating, antioxidant and neuroprotective roles. Accordingly, MT-I+II reduce CNS activation of macrophages and lymphocytes including expression of proinflammatory cytokines IL-1b, IL-6, IL-12 and TNF-a. Moreover, MT-I+II are antioxidant and antiapoptotic factors counteracting reactive oxygen species (ROS)/oxidative stress, neurodegeneration and apoptotic cell death, whereby the delayed (secondary) tissue damage was inhibited after brain injury and 6-AN-toxicity. MT-I+II also diminish the primary CNS toxicity caused directly by 6-AN and the clinical outcome (mortality). Additionally, MT-I+II stimulate astrogliosis; expression of growth factors, their receptors and neurotrophins (TGFb, TGFb-Receptor, bFGF, bFGF-Receptor, VEGF, NT-3, NT-4/5, NGF); angiogenesis; and growth cone formation. Hence, MT-I+II enhance CNS tissue repair as seen clearly after the cryogenic injury, after which MT-I+II promote substitution of the necrotic lesion cavity with a glial scar tissue including revascularization. In the surrounding tissue, MT-I+II stimulate growth cone formation and outgrowths of surviving neurons situated outside the lesioned area; while inside the lesion, normal neurons or neuronal cell bodies were never seen. The angiogenic actions of MT-I+II were supported by comparing various genotypes like GFAP-IL6 mice; MT-I+II deficient GFAP-IL6 (GFAP-IL6/MT-KO) mice; MT-I+II heterozygous GFAP-IL6 mice (GFAP-IL6-MT+/- mice); double-transgenic IL-6 and MT-I overexpressors (GFAP-IL6/TgMT mice); MT-KO mice; and TgMT mice. The IL-6 overexpressors are suitable for this as they spontaneously develop proliferative angiopathy/angiogenesis, which is inhibited by MT-I+II deficiency and enhanced by MT-I overexpression. In fact, angiogenesis was highest in the MT-I overexpressing TgMT and GFAP-IL6/TgMT mice, even though the TgMT mice show quite low IL-6 levels as MT-I+II inhibit brain IL-6 mRNA and protein. Moreover, GFAP-IL6/TgMT and TgMT and GFAP-IL6 genotypes were lesioned along wildtype controls in order to identify the roles of IL-6 versus MT-I+II. Although IL-6 induces CNS protection, this could be due to IL-6-induced MT-I+II, as neuroprotection and recovery are associated with MT-I+II levels only and not with IL-6 or inflammation: The more MT-I+II, the less neuropathology. The MT-I+II actions seen after brain injury and 6-AN-toxicity are induced by both endogenous MT-I overexpression and exogenous MT-II treatment. As presented here for the first time, analogous therapeutic effects are obtained after brain injury by using native or recombinant MT-I or MT-II derived from diverse non-mammalian and mammalian species like drosophila, mouse, rabbit, horse and human. Treatment with these MT-I and MT-II proteins significantly reduce inflammation, oxidative stress, neurodegeneration and apoptotic cell death after brain injury, while astroglia is stimulated. This indicates that MT-I+II function independently of species of origin. Previously, we showed that MT-I+II also ameliorate autoimmune, excitotoxic and inflammatory CNS disorders, and independent groups have confirmed this and have in fact added that MT-I+II are also major neuroprotective factors during ischemia and motor neuron disease. As emerging data validate these functions in human tissue and neurological patients, MT-I+II seem to demonstrate potentials as therapeutic targets for the treatment of CNS disorders.

AB -   This doctoral thesis describes the expression and roles of Metallothioneins I and II (MT-I+II) during CNS pathology. MT-I+II expression increases significantly in reactive astrocytes and microglia/macrophages after traumatic brain injury (cryogenic lesion in cerebral cortex) and brain stem toxicity induced by the gliotoxin 6-aminonicotinamide (6-AN). Interleukin-6 (IL-6) is a key inducer of brain MT-I+II, as judged by using genetic IL-6 deficient mice (IL-6 knock-out (IL-6KO) mice) and IL-6 overexpressing (GFAP-IL6) mice subjected to brain injury. These studies also indicate that IL-6 and/or IL-6-induced MT-I+II exert neuroprotective functions. To study MT-I+II roles in CNS, genetically modified mice with MT-I+II deficiency (MT-I+II knock-out (MT-KO) mice) or transgenic MT-I overexpression (TgMT mice) were applied along wildtype controls; as well as wildtype, and MT-KO mice receiving exogenous MT-I or MT-II treatment were examined. Both MT-KO and TgMT genotypes and mice receiving exogenous MT were studied after cryogenic brain injury and 6-AN-induced toxicity in brain stem. These experiments overall show that MT-I+II have significant immunomodulating, antioxidant and neuroprotective roles. Accordingly, MT-I+II reduce CNS activation of macrophages and lymphocytes including expression of proinflammatory cytokines IL-1b, IL-6, IL-12 and TNF-a. Moreover, MT-I+II are antioxidant and antiapoptotic factors counteracting reactive oxygen species (ROS)/oxidative stress, neurodegeneration and apoptotic cell death, whereby the delayed (secondary) tissue damage was inhibited after brain injury and 6-AN-toxicity. MT-I+II also diminish the primary CNS toxicity caused directly by 6-AN and the clinical outcome (mortality). Additionally, MT-I+II stimulate astrogliosis; expression of growth factors, their receptors and neurotrophins (TGFb, TGFb-Receptor, bFGF, bFGF-Receptor, VEGF, NT-3, NT-4/5, NGF); angiogenesis; and growth cone formation. Hence, MT-I+II enhance CNS tissue repair as seen clearly after the cryogenic injury, after which MT-I+II promote substitution of the necrotic lesion cavity with a glial scar tissue including revascularization. In the surrounding tissue, MT-I+II stimulate growth cone formation and outgrowths of surviving neurons situated outside the lesioned area; while inside the lesion, normal neurons or neuronal cell bodies were never seen. The angiogenic actions of MT-I+II were supported by comparing various genotypes like GFAP-IL6 mice; MT-I+II deficient GFAP-IL6 (GFAP-IL6/MT-KO) mice; MT-I+II heterozygous GFAP-IL6 mice (GFAP-IL6-MT+/- mice); double-transgenic IL-6 and MT-I overexpressors (GFAP-IL6/TgMT mice); MT-KO mice; and TgMT mice. The IL-6 overexpressors are suitable for this as they spontaneously develop proliferative angiopathy/angiogenesis, which is inhibited by MT-I+II deficiency and enhanced by MT-I overexpression. In fact, angiogenesis was highest in the MT-I overexpressing TgMT and GFAP-IL6/TgMT mice, even though the TgMT mice show quite low IL-6 levels as MT-I+II inhibit brain IL-6 mRNA and protein. Moreover, GFAP-IL6/TgMT and TgMT and GFAP-IL6 genotypes were lesioned along wildtype controls in order to identify the roles of IL-6 versus MT-I+II. Although IL-6 induces CNS protection, this could be due to IL-6-induced MT-I+II, as neuroprotection and recovery are associated with MT-I+II levels only and not with IL-6 or inflammation: The more MT-I+II, the less neuropathology. The MT-I+II actions seen after brain injury and 6-AN-toxicity are induced by both endogenous MT-I overexpression and exogenous MT-II treatment. As presented here for the first time, analogous therapeutic effects are obtained after brain injury by using native or recombinant MT-I or MT-II derived from diverse non-mammalian and mammalian species like drosophila, mouse, rabbit, horse and human. Treatment with these MT-I and MT-II proteins significantly reduce inflammation, oxidative stress, neurodegeneration and apoptotic cell death after brain injury, while astroglia is stimulated. This indicates that MT-I+II function independently of species of origin. Previously, we showed that MT-I+II also ameliorate autoimmune, excitotoxic and inflammatory CNS disorders, and independent groups have confirmed this and have in fact added that MT-I+II are also major neuroprotective factors during ischemia and motor neuron disease. As emerging data validate these functions in human tissue and neurological patients, MT-I+II seem to demonstrate potentials as therapeutic targets for the treatment of CNS disorders.

KW - Faculty of Health and Medical Sciences

M3 - Journal article

VL - 1

SP - 1

EP - 23

JO - The Danish Medical Association Publishing House

JF - The Danish Medical Association Publishing House

IS - 1

ER -

ID: 13621148